ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Eight Win ASCO Young Investigator Awards

August 22, 1986

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

January 17, 1992

Frozen Section Analysis Helps Avoid Second Surgery

September 30, 2005

HEW Secretary Tells Ethics Board To Take Up Issue of Compensation

September 28, 1979

Funding Opportunities

November 15, 2002

In Brief: Appropriations Bill Hung Up In Senate; Paul Black To Head B.U. Humphrey Center

September 21, 1979